Clinical Trials

Other solid neoplasmThoracic

117 enrolled 23 charts

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT02535312 2026-03-18

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Other solid neoplasmThoracic

30 enrolled 15 charts

Mesothelioma, Malignant

NCT05019716 2026-03-18

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Phase 1/2 Not yet recruiting

36 enrolled

Advanced NUT Carcinoma

NCT06694454 2026-03-18

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

60 enrolled

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT04083599 2026-03-16

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

DermatologicGastrointestinalHead & NeckThoracic

350 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT05410145 2026-03-12

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

442 enrolled

KRAS P.G12C

NCT07466160 2026-03-12

A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors

280 enrolled

Other solid neoplasm

Solid Tumor

NCT05229497 2026-03-09

A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

154 enrolled

Advanced Malignant Tumors

NCT06162221 2026-03-09

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

616 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

626 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT06772623 2026-02-27

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

252 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06996782 2026-02-24

ALTAIR

152 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05789082 2026-02-20

KRAScendo 170

320 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03734692 2026-02-12

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

24 enrolled 59 charts

Ovarian Cancer Recurrent

NCT07397338 2026-02-09

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

370 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07392541 2026-02-06

Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer

29 enrolled

Advanced Biliary Tract Carcinoma

NCT06405230 2026-02-03

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

272 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06428409 2026-01-22

MK-9999-02A

220 enrolled

Biliary Tract Neoplasms, Colorectal Neoplasms

NCT04486833 2026-01-21

Acclaim-1

158 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06548412 2026-01-20

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

50 enrolled

Biliary Tract Neoplasms

NCT06741644 2026-01-09

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

660 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT02989584 2026-01-07

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

54 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04203160 2025-12-31

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

Phase 1/2 Terminated

75 enrolled 17 charts

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04711824 2025-12-23

SOLARA

41 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06512051 2025-12-23

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

248 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04495296 2025-12-19

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

320 enrolled

Advanced Cancer

NCT03281369 2025-12-15

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

214 enrolled

Esophageal Neoplasms

NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

119 enrolled

Advanced Lung Cancer

NCT06040970 2025-12-02

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

54 enrolled

Ovarian Neoplasms, Uterine Neoplasms

NCT07258979 2025-12-02

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

202 enrolled

Nasopharyngeal Carcinoma, Recurrence

NCT07256782 2025-12-01

A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors

444 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05516914 2025-11-28

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

490 enrolled

Tumor-Agnostic

Neoplasms

NCT03288545 2025-11-10

EV-103

348 enrolled 1 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT02393794 2025-10-06

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

51 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05407675 2025-10-03

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

68 enrolled 27 charts

Tumor-Agnostic

Neoplasms

NCT04956640 2025-09-25

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

GastrointestinalGynecologicThoracic

540 enrolled

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06531434 2025-09-22

Establishing Best Treatment Strategy for T4 Esophageal Cancer

22 enrolled

Esophageal Cancer TNM Staging Primary Tumor (T) T4

NCT02432378 2025-06-19

Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines

Phase 1/2 Terminated

25 enrolled

Ovarian Neoplasms

NCT06859775 2025-06-06

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

100 enrolled

Uterine Cervical Neoplasms, Recurrence

NCT06802835 2025-05-16

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

148 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT06956716 2025-05-04

Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma

30 enrolled

Advanced Intrahepatic Cholangiocarcinoma

NCT02795988 2025-04-16

A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer

64 enrolled 20 charts

Adenocarcinoma, Gastrointestinal Neoplasms, Neoplasm Metastasis

NCT02365766 2025-03-18

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

83 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05784012 2025-03-13

RADIAN

34 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06494943 2025-02-25

Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC

27 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02202772 2025-02-24

CGC

51 enrolled

Carcinoma, Neoplasms, Recurrence

NCT03167164 2025-02-21

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Phase 1/2 Withdrawn

Dermatologic

Carcinoma, Merkel Cell

NCT03167177 2025-02-21

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1/2 Withdrawn

Dermatologic

Melanoma

NCT03169738 2025-02-21

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Phase 1/2 Withdrawn